Acquired KRAS mutations during progression of colorectal cancer metastases: Possible implications for therapy and prognosis

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 3, 2010, Pages 605-609

  Bouchahda, Mohamed ^a,b,c,e   Karaboué, Abdoulaye ^a,b,c   Saffroy, Raphaël ^a,c   Innominato, Pasquale ^a,b,c   Gorden, Lee ^a,d   Guettier, Catherine ^a,c   Adam, René ^a,b,c   Lévi, Francis ^a,b,c  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d VANDERBILT UNIVERSITY   (United States)

^e HÔPITAL PAUL BROUSSE   (France)

Author keywords

Acquired; Colorectal cancer; KRAS mutation; Metastases

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; FLUOROURACIL; GENOMIC DNA; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ACNE; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RESISTANCE; CANCER SURGERY; CASE REPORT; CODON; COLON ADENOCARCINOMA; COLON RESECTION; COLORECTAL CANCER; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HEPATIC ARTERY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CANCER; LIVER METASTASIS; LIVER RESECTION; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; POLYPOSIS; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; TREATMENT RESPONSE; TUMOR VOLUME; COLORECTAL TUMOR; DRUG RESISTANCE; FOLLOW UP; GENETICS; LIVER TUMOR; METASTASIS; MULTIDRUG RESISTANCE; MUTATION; PATHOLOGY; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; MUTATION; NEOPLASM METASTASIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RETROSPECTIVE STUDIES;

EID: 77954668198     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1298-9     Document Type: Article

References (22)

1. Linardou H, Dahabreh IJ, Kanaloupiti D et al (2008) Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 9:962-997
2. Milano G, Etienne-Grimaldi MC, Dahan L et al (2008) Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol 19:2033-2038
3. Cappuzzo F, Varella-Garcia M, Finocchiaro G et al (2008) Primary resistance to cetuximab therapy in EGFR FISH-positive colo-rectal cancer patients. Br J Cancer 99:83-89
4. American Society of Clinical Oncology provisional clinical opinion (2009) Testing for KRAS gene mutations in patients with met-astatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096
5. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG (2009) KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 27:1130-1136
6. Lièvre A, Bachet JB, Boige V et al (2008) KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 26:374-379
7. Yang S, Farraye FA, Mack C, Posnik O, O'Brien MJ (2004) BRAF and KRAS mutations in hyperplastic polyps and serrated adenomas of the colorectum: relationship to histology and CpG island methylation status. Am J Surg Pathol 28:1452-1459
8. Velho S, Moutinho C, Cirnes L et al (2008) BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 8:255
9. Artale S, Sartore-Bianchi A, Veronese SM et al (2008) Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26:4217-4219
10. Molinari F, Martin V, Saletti P et al (2009) Differing deregulation of EGFR and downstream proteins in primary colorectal cancer and related metastatic sites may be clinically relevant. Br J Cancer 100:1087-1094
11. Loupakis F, Pollina L, Stasi I et al (2009) PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. J Clin Oncol 27:2622-2629
12. Santini D, Loupakis F, Vincenzi B et al (2008) High concordance of KRAS status between primary colorectal tumors and related metastatic sites: implications for clinical practice. Oncologist 13:1270-1275
13. Badalian G, Barbai T, Rásó E, Derecskei K, Szendrôi M, Tímár J (2007) Phenotype of bone metastases of non-small cell lung cancer: epidermal growth factor receptor expression and K-RAS mutational status. Pathol Oncol Res 13:99-104
14. Kalikaki A, Koutsopoulos A, Trypaki M et al (2008) Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC. Br J Cancer 99:923-929
15. Dexter DL, Leith JT (1986) Tumor heterogeneity and drug resistance. J Clin Oncol 4:244-257
16. Sweeney C, Boucher KM, Samowitz WS et al (2009) Oncogenetic tree model of somatic mutations and DNA methylation in colon tumors. Genes Chromosomes Cancer 48:1-9
17. Kimura K, Nagasaka T, Hoshizima N et al (2007) No duplicate K-RAS mutation is identified on the same allele in gastric or colo-rectal cancer cells with multiple K-RAS mutations. J Int Med Res 35:450-457
18. Losi L, Baisse B, Bouzourene H, Benhattar J (2005) Evolution of intratumoral genetic heterogeneity during colorectal cancer progression. Carcinogenesis 26:916-922
19. Baisse B, Bouzourene H, Saraga EP, Bosman FT, Benhattar J (2001) Intratumor genetic heterogeneity in advanced human colo-rectal adenocarcinoma. Int J Cancer 93:346-352
20. Pintilie M, Iakovlev V, Fyles A, Hedley D, Milosevic M, Hill RP (2009) Heterogeneity and power in clinical biomarker studies. J Clin Oncol 27:1517-1521
21. Holdhoff M, Schmidt K, Donehower R, Diaz LA Jr (2009) Analysis of circulating tumor DNA to confirm somatic KRAS mutations. J Natl Cancer Inst 101:1284-1285
22. Adam R, Pascal G, Castaing D et al (2004) Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases? Ann Surg 240:1052-1061